Add BrightSurf on Google Email

Science News for September 8, 2019


Phase 1 study shows novel KRAS inhibitor well tolerated by patients with adenocarcinoma and non-small cell lung cancer

A Phase 1 study demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation. The therapy, AMG 510, showed encouraging anti-tumor activity with no dose-limiting toxicities or adverse events leading to discontinuation.

Nivolumab combined with ipilimumab safe as first-line therapy for lung cancer patients

Research presented at the IASLC 2019 World Conference on Lung Cancer found that combining nivolumab with ipilimumab showed improved efficacy in patients with advanced non-small cell lung cancer (NSCLC), particularly those with high TMB or higher tumor PD-L1 expression. The safety profile of this combination therapy was also consistent ...

Keynote 189: Tumor mutational burden not significantly associated with efficacy of pembrolizumab

Researchers studied the relationship between tumor mutational burden and response to immunotherapy with pembrolizumab. The study found that high or low TMB levels did not significantly impact overall survival, progression-free survival, or objective response rates for patients with metastatic nonsquamous non-small cell lung cancer.